CytoDyn Inc (PK:CYDY)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1111 Main St Ste 660
VANCOUVER WA 98660-2970
Tel: N/A
Website: https://www.cytodyn.com
IR: See website
<
Key People
Jacob P. Lalezari
Chief Executive Officer
Mitchell Cohen
Interim Chief Financial Officer
Max Lataillade
Senior Vice President and Head of Clinical Development
Tyler Blok
Corporate Secretary, Chief Legal Officer
   
Business Overview
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.
Financial Overview
For the three months ended 31 August 2024, CytoDyn Inc revenues was not reported. Net income applicable to common stockholders totaled $18.9M vs. loss of $11.9M. Net income reflects Finance charges decrease of 98% to $14K (expense), loss on induced conversion decrease of 41% to $1.2M (expense), General and administrative - Balancing decrease of 32% to $1M (expense).
Employees: 9 as of Aug 15, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $153.74M as of Aug 31, 2024
Annual revenue (TTM): $0.00M as of Aug 31, 2024
EBITDA (TTM): $9.02M as of Aug 31, 2024
Net annual income (TTM): -$20.53M as of Aug 31, 2024
Free cash flow (TTM): -$1.05M as of Aug 31, 2024
Net Debt Last Fiscal Year: $4.00M as of Aug 31, 2024
Shares outstanding: 1,219,841,932 as of Sep 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.